Epidemiological data requirements for vitamin D fortification

Epidemiological Data Requirements for Vitamin D Fortification: A Practitioner's Map of the Terrain

When we look at the vitamin D status of adults across Europe, the numbers tell us something we already suspected but rarely say out loud: roughly four in every ten people in the general population carry serum 25-hydroxyvitamin D concentrations below 50 nmol/L, and about thirteen percent fall below the more conservative 30 nmol/L threshold used in many European surveillance studies. That is not a fringe statistic about a marginalised few — it is a population-wide signal of widespread, low-grade deficiency that crosses income brackets, latitudes, and age groups. For those of us working in community nutrition and population health, those figures are not just descriptive; they are a roadmap, telling us exactly where fortification policy must begin to look for evidence and where it has, so far, failed to look at all.

The reason this matters for fortification specifically is that designing a food vehicle, a target intake range, and a regulatory framework without first gathering robust epidemiological data is like prescribing medicine before taking the patient's history. We need to know who is deficient, by how much, in which seasons, through which dietary patterns, and across which demographics — because every one of those variables changes the dose, the carrier, and the population coverage. Below, we walk through the five data domains that any rigorous vitamin D fortification programme must establish before policy is written, food matrices are selected, or upper intake levels are debated.

Defining Serum 25(OH)D Thresholds and What They Actually Tell Us

The cornerstone biomarker for population vitamin D status is serum 25-hydroxyvitamin D, or 25(OH)D, the circulating metabolite that reflects both dietary intake and cutaneous synthesis over the preceding weeks. Epidemiological studies across Europe have converged on two practical cut-offs: a deficiency threshold at concentrations below 30 nmol/L (12 ng/mL), which captures individuals at high clinical risk of musculoskeletal complications, and an insufficiency threshold at below 50 nmol/L (20 ng/mL), which marks the broader population whose status may compromise other physiological functions we are still characterising. Internationally, recommended targets range from ≥25 to ≥50 nmol/L depending on the health outcome being prioritised — bone health alone tolerates the lower end, while emerging evidence on immune and metabolic function often pushes policymakers toward the upper end of that range.

What this means in practice is that surveillance systems must report prevalence at both thresholds, not just one, because the policy implications differ substantially. A region with 13 percent below 30 nmol/L and 40 percent below 50 nmol/L — the rough European averages we cited above — is not facing a problem that can be fixed by targeted supplementation alone; it requires a population-level dietary intervention such as fortification to shift the central tendency of the distribution upward.

A biomarker is only as useful as the cut-off we choose to apply around it, and the cut-off we choose shapes who we are willing to leave behind.

We should also acknowledge openly that there is no single globally unified cut-off for "optimal" 25(OH)D, because the consensus varies between ≥25, ≥50, and ≥75 nmol/L depending on which outcome is being measured. This is not a flaw in the science — it is the science honestly reflecting that bone, immune function, and pregnancy outcomes each have their own dose-response curves. For fortification planning, this means selecting a defensible threshold (most European programmes anchor to ≥50 nmol/L for the general adult population), documenting the rationale, and reporting prevalence consistently against that benchmark across surveys.

Mapping Dietary Intake and Seasonal UVB Exposure

The second data domain is habitual dietary intake, and this is where the analysis becomes genuinely difficult because the food sources of vitamin D are few, narrow, and unequally distributed. Natural dietary sources — oily fish, egg yolks, certain mushrooms exposed to ultraviolet light, and liver — are not consumed with equal frequency across populations. In Northern Europe, oily fish may be a regular part of the diet; in landlocked or lower-income communities, it is often a luxury. When we layer fortification onto this uneven baseline, the food vehicle choice becomes the most consequential policy decision a programme will make.

This is why epidemiological intake assessments must be granular enough to capture life-stage variation (infancy, adolescence, pregnancy, older age), ethnic variation in traditional diets, and seasonal variation in consumption patterns. A national fortification programme for fluid milk, for instance, will systematically miss populations with low dairy intake, including many adults of South Asian, East Asian, and African heritage living in European cities, and will only partially reach children already consuming fortified products through other channels.

The other half of the intake picture is cutaneous synthesis from UVB exposure, which varies dramatically with season, latitude, skin pigmentation, clothing, and time spent outdoors. At latitudes above approximately 35°N, cutaneous vitamin D synthesis becomes negligible during late autumn and winter months, and this seasonal trough drives the well-documented winter decline in population 25(OH)D concentrations in countries such as the United Kingdom, Germany, Poland, and the Nordic states. Surveillance systems should therefore collect 25(OH)D data across at least two seasons — typically late winter and late summer — to capture both the trough and the recovery, rather than reporting a single annual figure that masks the oscillation entirely.

Seasonality is not a footnote; for half the year, sunlight stops doing the work that diet and fortification must take up instead.

Identifying Vulnerable Demographics and Age-Related Declines

When we talk about "at-risk populations" in public health, we usually mean three overlapping groups: infants and young children, pregnant and lactating women, and older adults. Each carries a distinct epidemiological signature that fortification planning must address, and the data requirements for each are different.

For infants, the key variables are feeding mode (breast milk contains relatively little vitamin D), supplementation policy in the first year of life, and the timing of weaning onto fortified complementary foods. Population surveys rarely collect these data at the resolution needed, which is why many national programmes rely on consensus intake recommendations of 10 μg (400 IU) per day for infants rather than population-wide biomarker data.

For pregnant and lactating women, the central question is whether maternal status is sufficient to support fetal skeletal mineralisation and neonatal reserves, and here the data gap is substantial. Most European countries do not have nationally representative 25(OH)D data for pregnant cohorts, leaving clinicians and policymakers to extrapolate from women's data or from small regional studies.

For older adults, the picture is the starkest. Cutaneous vitamin D synthesis decreases by roughly four-fold with advancing age compared with younger adults, and this reduction is compounded by reduced time outdoors, clothing that covers more of the body, and the higher prevalence of institutional living in northern latitudes. The epidemiological consequence is that older adults living in care homes in Northern Europe during winter often have the lowest 25(OH)D concentrations of any demographic, and the very food vehicles (fortified dairy, margarines) that work for younger adults may be less consistently consumed in this group. A serious fortification policy must therefore disaggregate its surveillance data by age band — at minimum, by children, working-age adults, and adults over 65 — and where possible, by setting (community-dwelling vs. institutionalised).

Evaluating European Policy Frameworks: Mandatory Versus Voluntary

The European landscape for vitamin D fortification is, frankly, a patchwork, and the epidemiological data we have just discussed is what makes the patchwork visible in the first place. Under Regulation (EC) No 1925/2006, micronutrient addition to foods is permitted across the European Union, but the decision to make fortification mandatory — that is, to require it in specified food categories at specified levels — remains with each Member State. The result is that a small number of countries have moved decisively to mandatory frameworks while the majority continue to operate voluntary regimes driven by manufacturer choice.

Mandatory vitamin D fortification is currently adopted by a limited set of European countries. Finland has long required fortification of homogenised skim milk, Sweden mandates fortification of low-fat dairy products and plant-based dairy alternatives, and Belgium and Poland have established mandatory fortification of fat spreads (margarine and similar products). These are deliberate choices of food vehicle — typically, the staples that already reach the largest proportion of the population at relatively consistent intake levels — and they reflect, in each case, an attempt to shift population status without relying on individual behaviour change.

The voluntary model, which dominates the continent, has produced measurable results in specific product categories — many breakfast cereals, plant-based milks, and fat spreads carry meaningful added vitamin D — but the coverage is uneven. Epidemiological surveillance in countries with voluntary frameworks consistently shows that the populations most at risk of deficiency (lower-income households, ethnic minority groups, institutionalised elders) are often the least likely to consume the voluntarily fortified products at the doses assumed in policy modelling. This is the systemic barrier at the heart of the equity question, and it is precisely the kind of finding that surveillance data is designed to surface.

For policymakers reviewing their national programme, the practical question is not "mandatory or voluntary" in the abstract but "what is our current population 25(OH)D distribution, which demographic strata fall below the chosen threshold, and which food vehicle reaches those strata most reliably?" The WHO and FAO guidelines on food fortification with micronutrients, first published in 2006 and still foundational today, lay out this decision logic in detail, and the UK Scientific Advisory Committee on Nutrition's May 2024 report on fortifying foods and drinks with vitamin D extended the evidence base specifically for the British context. National policy reviews since then — including the European vitamin D fortification policy landscape review of April 2026 — have generally moved toward recommending at least one mandatory staple vehicle where voluntary coverage has demonstrably left a residual deficiency burden.

Mitigating Over-Exposure and Under-Fortification in Targeted Groups

A common objection to mandatory fortification is the risk of pushing already-replete individuals above safe upper intake levels, and this is a legitimate epidemiological concern that must be addressed in the data itself. The tolerable upper intake level for vitamin D in adults, set by the European Food Safety Authority at 100 μg (4,000 IU) per day, is far above what a reasonable fortification programme delivers even to heavy consumers of fortified staples, but the picture changes when fortification is layered on top of voluntary supplement use.

Surveillance data must therefore capture not only dietary intake from food (including fortified foods) but also the prevalence of dietary supplement use in the population, ideally disaggregated by demographic group. In countries where supplement use is high among health-conscious, higher-income, more educated adults, the risk of excess is concentrated precisely in the population least likely to be deficient — which is, from an equity standpoint, the wrong direction. Conversely, in lower-income and minority populations with low supplement use and low fortified-staple intake, the risk is that mandatory fortification at a modest dose still leaves them below threshold because the food vehicle does not reach them.

The mitigation strategy here is one we have seen work in the Finnish and Swedish contexts: select a staple vehicle with high and reasonably uniform population penetration (dairy and fat spreads in Nordic diets), set the fortification dose conservatively so that even high consumers do not approach the upper intake level, and couple the mandatory programme with targeted supplementation for the demographic groups the vehicle still misses. This is the equity architecture of a mature fortification policy, and it is only possible to design when the underlying epidemiological data tells us both who is under-dosed and who is at risk of being over-dosed.

Good fortification policy does not aim to raise the average; it aims to lift the tail of the distribution without overshooting the head.

For researchers and programme designers, the practical implication is that intake assessment must be paired with biomarker surveillance on a recurring cycle — typically every five to ten years — so that the policy can be adjusted as dietary patterns, supplement use, and population demographics shift. Vitamin D status is not a static target; it is a moving distribution shaped by migration, urbanisation, ageing populations, and changing dietary norms.

Closing: From Surveillance to Systemic Adjustment

The epidemiological data we have surveyed here — serum 25(OH)D thresholds, dietary intake patterns, seasonal UVB exposure, age-related synthesis decline, ethnic variation, and the European patchwork of mandatory versus voluntary fortification — is not an academic exercise. It is the working file of anyone serious about moving population vitamin D status out of the deficiency range. And it tells us, with a clarity we should not look away from, that voluntary frameworks alone have not closed the gap in most countries, that older adults and ethnic minority populations are consistently under-served by current staple-vehicle choices, and that seasonal troughs are structural rather than incidental.

For the practitioners among us — the epidemiologists, nutritionists, policymakers, and community health advocates reading this — the call to action is concrete. Audit your national 25(OH)D surveillance data for demographic disaggregation. Identify which population strata the current voluntary fortification framework is leaving behind. Evaluate whether a mandatory staple-vehicle approach, modelled on the Finnish or Swedish precedents, would reach those strata more reliably. And design the surveillance cycle that will let you know, in five years' time, whether the adjustment worked. Nutritional equity is not an aspiration; it is a measurement problem with a measurement solution, and the data requirements we have walked through here are the first step toward claiming that solution at last.